QIAGEN NV

Entdecken Sie, warum QIAGEN NV trotz kleiner Marktkapitalisierung im DAX 40 stabile Preise und defensive Wachstumschancen bietet – ein solides Fundament für langfristige Investoren.

QIAGEN NV has acquired Genoox, an AI-powered software provider, to enhance its digital offerings and expand its capabilities in genetic data analysis, positioning the company for growth in the rapidly evolving genomics landscape.

Qiagen NV has announced a strong start to 2025 with plans for a $500 million share buyback and a regular annual dividend, driven by its impressive first-quarter financial performance.